Development Strategy

QRxPharma’s pipeline includes patented clinical and preclinical stage drug candidates in the fields of pain therapy and neurodegenerative disease. The Company’s drug development strategy re-positions existing therapies for new clinical uses. This approach shortens transitions from bench to market providing for abbreviated development paths, efficient regulatory approvals, and new commercialisation value. QRxPharma’s most advanced asset is a “Dual Opioid®” drug for the treatment of moderate to severe pain. The Company’s lead drug compound, MoxDuo® IR (Q8003 IR) began Phase 3 clinical trials in November 2007.

QRx Pharma

Development Strategy